Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer

Figure 1 Flowchart of patient inclusion and exclusion. CRC: Colorectal cancer; RFA: Radiofrequency ablation; Combined: Radiofrequency ablation plus capecitabine; Only RFA: Radiofrequency ablation alone.

Figure 2 Kaplan-Meier curves. A: For overall survival in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 37.8 months); B: For progression-free survival in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 18.7 months); C: For local tumor progression in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 35.6 months).

Figure 3 Kaplan-Meier curves of colorectal cancer patients with lung metastases stratified by different treatment modalities, showing cumulative 1-year, 3-year, and 5-year rates. A: Overall survival; B: Progression-free survival; C: Local tumor progression. RFA: Radiofrequency ablation; Combined: Radiofrequency ablation plus capecitabine; Only RFA: Radiofrequency ablation alone.